|Table of Contents|

Dosimetric study on movement displacement that real-time monitoring by C-RAD Catalyst HD in intensity modulated radiotherapy after breast-conserving surgery for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
144-151
Research Field:
Publishing date:

Info

Title:
Dosimetric study on movement displacement that real-time monitoring by C-RAD Catalyst HD in intensity modulated radiotherapy after breast-conserving surgery for breast cancer
Author(s):
FANG Yongwen1; DENG Shunjian2; ZHANG Jun1; PENG Yinglin1; FANG Jianlan1
1.South China National Cancer Laboratory,Cancer Prevention and Treatment Center of Sun Yatsen University,Guangdong Guangzhou 510060,China;2.Guangzhou Xinhua University,Guangdong Guangzhou 510310,China.
Keywords:
C-RAD Catalyst HD; real-time monitoring; breast-conserving surgery for breast cancer; dosimetry
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.01.027
Abstract:
Objective:To analyze the real-time monitoring of body surface motion displacement of breast cancer patients by C-RAD Catalyst HD within fractions,and to give the recommended motion thresholds that should be set when using C-RAD Catalyst HD.Methods:Taking C-RAD Catalyst HD real-time monitoring of body surface movement displacement data of breast cancer patients as a reference,the proportion of movement displacement interval in the translation direction was analyzed,and the patient's movement law was simulated,and different displacement isocenters were substituted into the patient's QA plan to read the dosimetry parameter.Results:In the plan of displacement in the positive direction of Y(head and foot) and Z(anterior and posterior),the D2% and HI of the planned target area showed a linear increasing trend,and the D98%,V95%,CI of the planned target area and the dosimetry parameters of the organ at risk showed a linear increase.There was a linear decreasing trend,and the dosimetric parameters of the organ at risk were all within the clinically acceptable range.For the plan shifted in the negative direction,the change trend of the planned target dose and the dosimetric parameter of the organ at risk showed a linear increasing trend.The parameters of the planned target volume that did not meet the clinical prescription dose requirements:V95% of the planned target volume when the displacement in the positive direction exceeded 3 mm.D2% of the planned target volume when the displacement in the positive direction exceeded 5 mm.D2% and V95% of the planned target volume when the displacement in the negative direction exceeded 4 mm.Organ-at-risk dosimetry parameters beyond the dose reference limits:Dmean,V5 Gy in the affected lung and V40 Gy in the heart of left breast cancer patients with upward displacement of more than 3 mm in the negative direction,and when it exceeded 4 mm,Dmean of the unaffected breast,heart of left breast cancer patients(Dmean,V5 Gy,V30 Gy),and right breast cancer patients(Dmean of heart,V5 Gy of liver).V20 Gy of the affected lung when it exceeded 5 mm.Conclusion:When C-RAD Catalyst HD is used to monitor the motion displacement of breast cancer patients undergoing radiotherapy after breast conserving surgery,it is recommended to set a 3 mm motion threshold to control the linear accelerator beam out.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］陈茂山,吕青.《基于人口登记数据2000-2020年全球乳腺癌发病和死亡率分析》要点解读［J］.中国胸心血管外科临床杂志,2022,29(4):401-406. CHEN MS,LYU Q.Interpretation of "Global Breast Cancer Incidence and Mortality Analysis Based on Population Registration Data from 2000 to 2020"［J］.Chinese Journal of Thoracic and Cardiovascular Surgery,2022,29(4):401-406.
［3］DRABY S,MCGALE P,CORREA C,et al.Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:meta-analysis of individual patient data for 10 801 women in 17 randomised trials［J］.The Lancet,2011,378(9804):1707-1716.
［4］MORROW M,STROM EA,BASSETT LW,et al.Standard for breast conservation therapy in the management of invasive breast carcinoma［J］.CA:A Cancer Journal for Clinicians,2002,52(5):277-300.
［5］BARNETT GC,WILKINSON JS,MOODY AM,et al.The cambridge breast intensity-modulated radiotherapy trial:Patient-and treatment-related factors that influence late toxicity［J］.Clinical Oncology,2011,23(10):662-673.
［6］MUKEESH MB,QIAN W,WILKINSON JS,et al.Patient reported outcome measures(PROMs) following forward planned field-in field IMRT:Results from the cambridge breast IMRT trial［J］.Radiotherapy and Oncology,2014,111(2):270-275.
［7］PIGNOL J,TRUONG P,RAKOVITCH E,et al.Ten years results of the Canadian breast intensity modulated radiation therapy(IMRT) randomized controlled trial［J］.Radiotherapy and Oncology,2016,121(3):414-419.
［8］SCHUBERT LK,GONDI V,SENGBUSCH E,et al.Dosimetric comparison of left-sided whole breast irradiation with 3DCRT,forward-planned IMRT,inverse-planned IMRT,helical tomotherapy,and topotherapy［J］.Radiotherapy and Oncology,2011,100(2):241-246.
［9］BARNETT GC,WILKINSON J,MOODY AM,et al.A randomised controlled trial of forward-planned radiotherapy(IMRT) for early breast cancer:Baseline characteristics and dosimetry results［J］.Radiotherapy and Oncology,2009,92(1):34-41.
［10］WILLIAMS TM,MORAN JM,HSU S,et al.Contralateral breast dose after whole-breast irradiation:An analysis by treatment technique［J］.International Journal of Radiation Oncology?Biology?Physics,2012,82(5):2079-2085.
［11］李岩,刘莉莉,梁莉丽,等.影像引导对乳腺癌调强放射治疗精度的影响［J］.现代生物医学进展,2013,13(35):6913-6917. LI Y,LIU LL,LIANG LL,et al.Effect of image guidance on the precision of IMRT for breast cancer［J］.Advances in Modern Biomedicine,2013,13(35):6913-6917.
［12］陈明,李建彬,邓小武,等.中国放射治疗相关的器官运动管理指南［J］.中国肿瘤,2021,30(10):726-733. CHEN M,LI JB,DENG XW,et al.Guidelines for the management of organ movement related to radiotherapy in China［J］.China Oncology,2021,30(10):726-733.
［13］方涌文,刘镖水,肖亮杰,等.光学体表监测系统Catalyst HD的cPosition与cMotion功能在乳腺癌调强放疗中的应用［J］.中国医疗设备,2022,37(6):19-22,34. FANG YW,LIU BS,XIAO LJ,et al.Application of cPosition and cMotion functions of optical body surface monitoring system Catalyst HD in intensity-modulated radiotherapy for breast cancer［J］.China Medical Equipment,2022,37(6):19-22,34.
［14］方键蓝,方涌文,刘镖水,等.Catalyst HD光学体表引导发泡胶固定乳腺癌调强放疗摆位精度的研究［J］.实用医学杂志,2022,38(5):547-551. FANG JL,FANG YW,LIU BS,et al.Study on the placement accuracy of IMRT-guided styrofoam fixation for breast cancer with Catalyst HD optical body surface［J］.Journal of Practical Medicine,2022,38(5):547-551.
［15］张光伟,吴何苟,刘剑锋,等.光学表面监测系统自动摆位功能对乳腺癌放疗患者治疗精度及摆位时间的影响［J］.中国医学物理学杂志,2021,38(4):411-415. ZHANG GW,WU HG,LIU JF,et al.Influence of automatic positioning function of optical surface monitoring system on the treatment accuracy and positioning time of breast cancer radiotherapy patients［J］.Chinese Journal of Medical Physics,2021,38(4):411-415.
［16］DONOVAN EM,CIURLIONIS L,FAIRFOUL J,et al.Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk(IMPORT high trial)［J］.International Journal of Radiation Oncology Biology Physics,2011,79(4):1064-1072.
［17］MECHALAKOS J,YORKE E,MAGERAS GS,et al.Dosimetric effect of respiratory motion in external beam radiotherapy of the lung［J］.Radiotherapy and Oncology,2004,71(2):191-200.
［18］谢金莲,覃文,李博,等.乳腺癌保乳术后四种不同放疗计划模式的剂量学研究［J］.临床医学研究与实践,2022,7(3):56-61. XIE JL,QIN W,LI B,et al.Dosimetry study of four different radiotherapy planning modes after breast-conserving breast cancer surgery［J］.Clinical Medical Research and Practice,2022,7(3):56-61.
［19］中国医师协会放射肿瘤治疗医师分会.乳腺癌放射治疗指南(中国医师协会2020版)［J］.中华放射肿瘤学杂志,2021,30(4):321-342. Radiation Oncology Physicians Branch of Chinese Medical Doctor Association.Guidelines for Radiation Therapy of Breast Cancer(Chinese Medical Doctor Association 2020 Edition)［J］.Chinese Journal of Radiation Oncology,2021,30(4):321-342.
［20］林荫光,陈森,卢雱,等.乳腺癌术后放疗患者平静呼吸下胸壁运动和器官受照剂量的变化［J］.广西医学,2021,43(21):2530-2534. LIN YG,CHEN S,LU P,et al.Changes of chest wall motion and organ exposure dose under calm breathing in patients with postoperative radiotherapy for breast cancer［J］.Guangxi Medicine,2021,43(21):2530-2534.
［21］ARROYO-HERNANDEZ M,MALDONADO F,LOZANO-RYIZ F,et al.Radiation-induced lung injury:current evidence［J］.BMC Pulm Med,2021,21(1):9.
［22］LINGOS TI,RECHT A,VICINI F,et al.Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy［J］.Int J Radiat Oncol Biol Phys,1991,21(2):355-360.
［23］HANANIA AN,MAINWARING W,GHEBRE YT,et al.Radiation-induced lung injury［J］.Chest,2019,156(1):150-162.
［24］AUPERIN A,LE PECHOUX C,ROLLAND E,et al.Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer［J］.Journal of Clinical Oncology,2010,28(13):2181-2190.
［25］GAGLIARDI G,LAX I,RUTQVIST LE.Partial irradiation of the heart［J］.Seminars in Radiation Oncology,2001,11(3):224-233.
［26］何尧林.乳腺癌放疗摆位误差分析及其对心肺受量的影响［D］.南宁：广西医科大学,2015. HE YL.Error analysis of radiotherapy for breast cancer and its influence on cardiopulmonary load［D］.Nanning:Guangxi Medical University,2015.
［27］GIRAUD P,COSSET JM.Radiation toxicity to the heart:physiopathology and clinical data［J］.Bull Cancer,2004,91(Suppl 3):147-153.
［28］王军,王祎,刘青,等.三维放疗急性放射性心脏损伤类型及影响因素分析［J］.中华放射肿瘤学杂志,2013,22(3):213-216. WANG J,WANG Y,LIU Q,et al.Types and influencing factors of acute radiation-induced cardiac injury in three-dimensional radiotherapy［J］. Chinese Journal of Radiation Oncology,2013,22(3):213-216.
［29］DARBY SC,EWERTZ M,MCGALE P,et al.Risk of ischemic heart disease in women after radiotherapy for breast cancer［J］.N Engl J Med,2013,368(11):987-998.
［30］江林宫,孟鸿宇,张火俊.放射性肝损伤的研究进展［J］.世界华人消化杂志,2017,25(20):1811-1818. JIANG LG,MENG HY,ZHANG HJ.Research progress of radiation-induced liver injury［J］.World Chinese Journal of Digestion,2017,25(20):1811-1818.
［31］SHEN P,HUANG W,DAI Y,et al.Radiomics-based predictive model of radiation-induced liver disease in hepatocellular carcinoma patients receiving stereo-tactic body radiotherapy［J］.Biomedicines,2022,10(3):597.

Memo

Memo:
National Natural Science Foundation of China（No.81872459）;国家自然科学基金（编号：81872459）；广东省自然科学基金（编号：2018A030313666）；广东省广州市科技计划项目（编号：202206010154，202206010180）
Last Update: 2022-11-30